[Rosuvastatin in prevention of cardiac complications following surgical treatment of patients with vascular pathology].
The article deals with the findings of studying the use of rosuvastatin in patients after endured reconstructive operations on the brachiocephalic arteries and aortofemoral segment in order to prevent cardiac atherothrombotic complications. A total of thirty patients were given "Crestors" at a daily dose of 10 mg for two weeks prior to surgery and for two weeks postoperatively and were found to have a significant decrease in the average levels of total cholesterol and low-density lipoproteins, which was accompanied and followed by certain improvement in the functional state of the vascular wall, with no cardiac complications being observed in either case.
Pokrovskiĭ
A V
AV
Kuntsevich
G I
GI
Zotikov
A E
AE
Goloviuk
A L
AL
Burtseva
E A
EA
Ivanov
L O
LO
Suntsov
D S
DS
D000328:Adult; D000368:Aged; D001012:Aorta, Abdominal / Q000601:surgery; D050197:Atherosclerosis / Q000601:surgery*; D016122:Brachiocephalic Trunk / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D017700:Embolism, Cholesterol / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000009:adverse effects*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium